NEWARK, DE — The global CCR6 antagonists market is entering a high-growth phase, expanding from USD 1.0 billion in 2026 to USD 4.0 billion by 2036, registering a CAGR of 12.0%, according to Future Market Insights (FMI). Growth is being driven by increasing adoption of targeted immunotherapies, rising prevalence of autoimmune and inflammatory diseases, and expanding clinical trial...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Romaian
Portuguese (Brazil)
Greek